Elimination of donor-specific antibodies against HLA has been used to enable transplantation of HLA-incompatible kidneys from living donors. In contrast to two previous US studies, a UK study now reports that desensitization does not offer a survival benefit over remaining on the waitlist for a compatible organ.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Opelz, G. President's address. The Transplantation Society — Berlin 2012. Transplantation 95, 4–7 (2013).
Manook, M. et al. Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis. Lancet http://dx.doi.org/10.1016/S0140-6736(16)31595-1 (2017).
Süsal, C. et al. Determination of unacceptable HLA antigen mismatches in kidney transplant recipients: recommendations of the German Society for Immunogenetics. Tissue Antigens 86, 317–323 (2015).
Süsal, C. & Morath, C. Current approaches to the management of highly sensitized kidney transplant patients. Tissue Antigens 77, 177–186 (2011).
Montgomery, R. A. et al. Desensitization in HLA-incompatible kidney recipients and survival. N. Engl. J. Med. 365, 318–326 (2011).
Orandi, B. J. et al. Survival benefit with kidney transplants from HLA-incompatible live donors. N. Engl. J. Med. 374, 940–950 (2016).
Bentall, A. et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am. J. Transplant. 13, 76–85 (2013).
Gondos, A., Döhler, B., Brenner, H. & Opelz, G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 95, 267–274 (2013).
Süsal, C. et al. Donor-specific antibodies require preactivated immune system to harm renal transplant. EBioMedicine 9, 366–371 (2016).
Opelz, G. et al. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation 99, 400–404 (2015).
Acknowledgements
We would like to thank Dr Undine Samuel from the Eurotransplant Foundation, Leiden, Netherlands and Dr Abdullah Sakarcan from Reading, Pennsylvania, USA, for useful information on sensitized patients in the Eurotransplant region and the USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.S. has received lecture fees from Fresenius and Miltenyi, who produce immunoadsorption devices for desensitization. G.O. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Süsal, C., Opelz, G. Desensitization and survival in kidney transplant recipients. Nat Rev Nephrol 13, 196–198 (2017). https://doi.org/10.1038/nrneph.2017.24
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.24